KRAS and non-small cell lung carcinoma: The miR-125b transfectants increased the ratio of M1 to M2 macrophages by > 6 fold as well as iNOS (M1 marker) and Arg-1 (M2 marker) ratios in TAMs by 300 fold over the untreated controls, indicating the successful repolarization of TAMs in a KRAS/p53 double mutant genetically engineered NSCLC mouse model and naïve mice through the intraperitoneal administration of macrophage-specific HA-PEI nanoparticles in their lung tissues as a promising strategy in anticancer immunotherapy (Gharavi et al., 2022; Zanganeh et al., 2022).